首页|Second Affiliated Hospital of Nanchang University Reports Findings in Lung Cance r (Tumor lymphangiogenesis index reveals the immune landscape and immunotherapy response in lung adenocarcinoma)
Second Affiliated Hospital of Nanchang University Reports Findings in Lung Cance r (Tumor lymphangiogenesis index reveals the immune landscape and immunotherapy response in lung adenocarcinoma)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
By a News Reporter-Staff News Editor at Robotics & Machine Learning Daily News Daily News – New research on Oncology - Lung Cancer is the subject of a report. According to news originating from Jiangxi, People’ s Republic of China, by NewsRx correspondents, research stated, “Lymphangiogenes is (LYM) has an important role in tumor progression and is strongly associated w ith tumor metastasis. However, the clinical application of LYM has not progresse d as expected.” Our news journalists obtained a quote from the research from the Second Affiliat ed Hospital of Nanchang University, “The potential value of LYM needs to be furt her developed in lung adenocarcinoma (LUAD) patients. The Sequencing data and cl inical characteristics of LUAD patients were downloaded from The Cancer Genome A tlas and GEO databases. Multiple machine learning algorithms were used to screen feature genes and develop the LYM index. Immune cell infiltration, immune check point expression, Tumor Immune Dysfunction and Exclusion (TIDE) algorithm and dr ug sensitivity analysis were used to explore the correlation of LYM index with i mmune profile and anti-tumor therapy. We screened four lymphangiogenic feature g enes (PECAM1, TIMP1, CXCL5 and PDGFB) to construct LYM index based on multiple m achine learning algorithms. We divided LUAD patients into the high LYM index gro up and the low LYM index group based on the median LYM index. LYM index is a ris k factor for the prognosis of LUAD patients. In addition, there was a significan t difference in immune profile between high LYM index and low LYM index groups. LUAD patients in the low LYM index group seemed to benefit more from immunothera py based on the results of TIDE algorithm.”
JiangxiPeople’s Republic of ChinaAsi aAdenocarcinomaCancerCyborgsDrugs and TherapiesEmerging TechnologiesHealth and MedicineImmunologyImmunotherapyLung CancerLung Diseases and C onditionsMachine LearningOncologyRisk and Prevention
NETL
NSTL
